argenx SE (NASDAQ:ARGX) Q4 2022 Earnings Conference Call March 2, 2023 8:30 AM ET Company Participants Beth DelGiacco - VP Corporate Communications and IR Tim Van Hauwermeiren - CEO Karl Gubitz - CFO Keith Woods - COO Conference Call Participants Tazeen Ahmad - Bank of America Securities Rajan Sharma - Goldman Sachs Thomas Smith - SVB Securities Brendan Smith - Cowen Yatin Suneja - Guggenheim Partners Myles Minter - William Blair Manos Mastorakis - Deutsche Bank Alex Nackenoff - Raymond James Allison Bratze ...

Fourth Quarter and Full Year 2022 Financial Results and Business Update March 2, 2023 Forward Looking Statements This presentation has been prepared by argenx se ("argenx" or the "company") for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a recommendation, promise or representation by the presenter or the company or any director, employee, agent, or adviser of the company. This presentation does not purport to be all-inclusi ...

argenx SE (NASDAQ:ARGX) Q2 2022 Earnings Conference Call July 28, 2022 8:30 AM ET Company Participants Beth DelGiacco - VP Corporate Communications and IR Tim Van Hauwermeiren - CEO Karl Gubitz - CFO Keith Woods - COO Conference Call Participants Danielle Brill - Raymond James Yaron Werber - Cowen Yatin Suneja - Guggenheim Partners Derek Archila - Wells Fargo Allison Bratzel - Piper Sandler Akash Tewari - Jefferies Matthew Harrison - Morgan Stanley Tazeen Ahmad - Bank of America Securities Thomas Smith - SV ...

Financial Performance - Argenx reported Q2 2022 net product revenues of $75 million[9], primarily driven by VYVGART sales[25] - US product net sales were $73.2 million in Q2 2022[20] - Japan product net sales were $1.5 million in Q2 2022[20] - The company ended Q2 with $2.6 billion in cash[7, 21] - R&D expenses for the second quarter were $126.9 million[21] - SG&A expenses for the second quarter were $127.8 million[21] VYVGART Launch and Expansion - Approximately 1400 patients are on VYVGART globally[27] - 85% of covered lives have broad coverage for VYVGART[34] - A J-Code for VYVGART went into effect on July 1, 2022[34] Pipeline Progress - A BLA submission for subcutaneous efgartigimod (SC) in gMG is expected by the end of 2022[7, 11] - ADHERE (CIDP) data is expected in Q1 2023[7] - ADVANCE-SC (ITP) and ADDRESS (PV) data are expected in the second half of 2023[7]

argenx SE (NASDAQ:ARGX) Q1 2022 Earnings Conference Call May 5, 2022 8:30 AM ET Corporate Participants Beth DelGiacco - VP Corporate Communications and Investor Relations Tim Van Hauwermeiren - Chief Executive Officer Luc Truyen - Chief Medical Officer Karl Gubitz - Chief Financial Officer Keith Woods - Chief Operating Officer Conference Call Participants Yatin Suneja - Guggenheim Matthew Harrison - Morgan Stanley Tazeen Ahmad - Bank of America Akash Tewari - Jefferies Yaron Werber - Cowen James Gordon - JP ...